The sale comes amid rising competition from brands such as Ayvakit, marketed by French major Sanofi. However, direct generic competition is expected to arrive only after 2029 in Europe and 2030 in the ...

Of the total 220 NSQ samples identified in August, includes several common medicines such as paracetamol, metformin combos (for diabetes), amoxicillin formulations (antibiotics), vitamin supplements ...

Approximately 96% completion, every certificate accounted for, with nothing overdue – this is what a quality head at an Indian formulation plant can pull up from her training dashboard in less than a ...

New York: A federal appeals court on Monday revived more than 500 private lawsuits against Tylenol maker Kenvue over the painkiller's alleged link to autism. The 2nd U.S. Circuit Court of Appeals in ...

Novo Nordisk's CagriSema shows significant weight loss benefits in diabetes patients, surpassing Eli Lilly's tirzepatide in ...

India's DCGI warns against the indiscriminate use of painkillers and antibiotics due to risks of chronic kidney disease, urging healthcare professionals to adhere to strict guidelines for medication.

Beacon Therapeutics has announced that their experimental gene therapy, laru-zova, significantly improves reading ability in ...

The biosimilar alternative, branded as Pebrilzo, is cleared for the treatment of HER2-positive breast cancer across multiple ...

New Delhi: Seventeen people have been arrested and hundreds of vials of life-saving drugs recovered by the Delhi Police's Crime Branch, busting an alleged multi-state racket involving counterfeit and ...

The company is racing to reassure markets that it can navigate patent expirations for semaglutide - the active ingredient in its anti-obesity drugs Ozempic and Wegovy franchises - in the early 2030s.

Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, ...

The San Diego, California -based ‌company is aiming to raise up to $371.9 million in the IPO by offering 21.9 million shares priced between $15 and $17 each.